Healthcare / Drug Manufacturers - Specialty & GenericTSXV
$1.16
+0.05 (+4.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $638000.00 · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-55.0%
↓Gross Margin
40.7%
↓Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.8%
FCF CAGR
—
FCF margin
-1.9%
FCF / Net income
0.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $28.9M · net income $-7.1M · FCF $-560000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $28.9M | $28.9M | $21.9M | $21.7M | $23.1M |
| Net Income | $-7.1M | $-7.1M | $-1.0M | $-922000.00 | $1.4M |
| EBITDA | $-4.2M | $-4.2M | $1.5M | $1.3M | $3.2M |
| EPS | -0.68 | -0.68 | -0.10 | -0.09 | 0.13 |
| Gross Margin | 40.7% | 40.7% | 59.7% | 64.5% | 69.7% |
| Operating Margin | -23.9% | -23.9% | -12.5% | -3.9% | 5.2% |
| Net Margin | -24.6% | -24.6% | -4.7% | -4.3% | 5.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.04 | 0.03 | 0.04 |
| Current Ratio | 1.04 | 1.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-560000.00 | $-560000.00 | $638000.00 | $1.8M | $1.5M |
| Returns | |||||
| ROE | -55.0% | -55.0% | -5.0% | -4.6% | 6.5% |
| Valuation | |||||
| P/E | — | — | — | — | 8.62 |
| EV/EBITDA | — | — | 1.79 | 6.59 | 2.36 |
| P/B | 0.94 | 0.94 | 0.44 | 0.72 | 0.56 |
| Growth & Yield | |||||
| Revenue Growth | 31.7% | 31.7% | 1.0% | -5.9% | — |
| EPS Growth | -580.0% | -580.0% | -11.1% | -169.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.10 → -0.68
Residual
+9.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.